SLC7A11 and multiple symmetric lipomatosis: In conclusion, TNBC is an aggressive and heterogeneous tumor that requires more selective treatment, and the xCT/NRF2/OSGIN1 axis is a novel specific target for the treatment of MSL/CL subtypes overexpressing SLC7A11, which may be more effective than GSH depletion.